Prolonged isolated thrombocytopenia (PT) is a serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). According to murine studies, endothelial progenitor cells (EPCs) play a crucial role in the regulation of hematopoiesis and thrombopoiesis in the bone marrow (BM) microenvironment. We previously showed that the reduced frequency of BM EPCs was an independent risk factor for the occurrence of PT following allo-HSCT. However, the functional role of BM EPCs and methods to improve the impaired BM EPCs in PT patients are unknown. In the current case-control study, we investigated whether the BM EPCs in PT patients NAC is safe and effective in PT patients. In summary, these results suggested that the reduced and dysfunctional BM EPCs are involved in the occurrence of PT. The defective BM EPCs in the PT patients can be quantitatively and functionally improved by NAC, indicating that NAC is a promising therapeutic approach for PT patients following allo-HSCT.
| I NT ROD U CTI ON
Prolonged isolated thrombocytopenia, which is defined as the engraftment of all peripheral blood cell lines other than platelet (PLT) count of less than 20 3 10 9 /L or dependence on PLT transfusions for more than 60 days following allogeneic hematopoietic stem cell transplantation (allo-HSCT), 1 is a serious complication associated with an increased risk of bleeding and poor overall survival following allo-HSCT. 2 Although several clinical risk factors, such as the dose of infused CD34 1 cells, infection, and graft-versus-host disease (GvHD), have been reported to be associated with the occurrence of prolonged Yuan Kong and Min-Min Shi contributed equally to this study.
Note added in proof:
We recently published another independent study entitled "N-acetyl-Lcysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant" in the British Journal of Haematology (2018;180(6):863-878. doi: 10.1111/bjh.15119). We wish to clarify that there is no overlap between the two manuscripts for both in vitro and in vivo data. For cell culture studies, the 25 patients we reported in the BJH article are different from the 30 patients we report in the present manuscript. The 10 NAC-treated patients reported in Fig. 7 of the BJH article are not included in the 20 NAC-treated patients reported in Fig. 4A of the present article.
isolated thrombocytopenia, 2-5 the pathogenesis underlying prolonged isolated thrombocytopenia remains unclear, and effective clinical management is challenging.
Platelet production is initiated by the proliferation and differentiation of hematopoietic stem cells (HSCs) and is concluded by the fragmentation of megakaryocytes (MKs). 6 Endothelial progenitor cells (EPCs) have been identified as key supporting elements for HSCs in the BM microenvironment. [7] [8] [9] [10] Effective cross-talk between MKs and EPCs in the BM microenvironment regulates MKs maturation and thrombopoiesis. 11, 12 Furthermore, Chen et al. reported that impaired BM EPCs lead to a reduced generation of platelets from MKs in a radiation-induced thrombocytopenia mouse model. 13 Additionally, according to our prospective case-control study, the reduced frequency of BM EPCs was an independent risk factor for prolonged isolated thrombocytopenia. 14 However, the functional roles of the BM EPCs and CD34 1 cells in prolonged isolated thrombocytopenia patients following allo-HSCT have not been previously reported.
Reactive oxygen species (ROS) are natural products of oxygen metabolism in cells that play an important role in the control of endothelial cell function and vascular integrity. 15 ROS are involved in the deregulation of apoptosis, migration, and endothelial cell dysfunction in many diseases, including hypercholesterolemia, atherosclerosis, diabetes, and heart failure. 15, 16 Moreover, ROS distinctly influence MKs maturation and platelet generation in the BM microenvironment. 6, 17, 18 The synthetic anti-oxidant N-acetyl-L-cysteine (NAC) is widely used to prevent exogenous ROS accumulation. 16, 19, 20 Treatment with NAC not only reversed endothelial cell dysfunction but also overcame the exhaustion of HSCs and enhanced the engraftment of human HSCs. 16, 21, 22 Nevertheless, whether NAC can improve the quantity and function of BM EPCs in prolonged isolated thrombocytopenia patients remains unknown.
In the current prospective case-control study, we investigated whether the quantity and function of BM EPCs and CD34 1 cells in prolonged isolated thrombocytopenia patients differed from those in good graft function patients. Moreover, we evaluated the effects of NAC on the number and function of cultivated BM EPCs derived from prolonged isolated thrombocytopenia patients and examined the underlying molecular mechanisms. Subsequently, a preliminary clinical study was performed to investigate the efficacy of NAC in prolonged isolated thrombocytopenia patients.
| M A TE RI A L S A ND M E TH ODS

| Patients and controls
In this prospective case-control study, transplant recipients were identified from a cohort who underwent an allotransplant between October 1, 2016, and June 30, 2017, at Peking University Institute of Hematology. In total, 30 patients who developed prolonged isolated thrombocytopenia were eligible. For each case, one matched transplant recipient with good graft function was selected from the same cohort after matching for age, pretransplant disease status, and posttransplant interval ("risk-set sampling"). 23 As shown in Supporting Information 
| Transplantation protocols
The donor selection, HLA-typing, graft harvesting, conditioning therapy, and GvHD prophylaxis were performed as previously described. 27, 31 The subjects were screened for CMV infection by serology. Real-time quantitative PCR was performed to detect CMV reactivation in the blood samples twice a week. CMV infection was treated with ganciclovir or foscarnet as previously described. 
| Cultivation and characterization of primary BM EPCs
Based on previous reports, 26, 33, 34 BMMNCs ( 
| Western blot analysis
After cultivating the BM EPCs for 7 days, proteins were separated on 10% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF, Millipore, Bedford) membranes. The membranes were incubated with antibodies against phospho-p38 MAPK, total p38, phospho-ERK, total ERK, phospho-JNK, total JNK, phospho-Akt, total Akt, and actin (Cell Signaling Technology) at the dilutions specified by the manufacturer's instructions. A horseradish peroxidase-conjugated secondary antibody was applied, and filters were developed using an ECL detection system (Pierce, Biotechnology Inc., Rockford).
| Histological analysis of human BM tissues
BM trephine biopsies were obtained from the posterior superior iliac spine and fixed with 4% paraformaldehyde. The frozen sections were used for immunofluorescence staining as previously described. 39 The mouse anti-human CD34 (Becton Dickinson) and rabbit anti-human CD133 (Abcam, Massachusetts) antibodies were added to the tissue section slides and incubated at 48C overnight. The goat anti-rabbit 555
and donkey anti-mouse 488 (Invitrogen, Oregon) antibodies were added at RT for 1 h. DAPI was applied to stain the nuclei, and the prepared slides were analyzed under a Leica TCS SP8 microscope (Leica Microsystems, Wetzlar, Germany). 
| Coculture of BM megakaryocytes and BM EPCs
The BM EPCs from the prolonged isolated thrombocytopenia patients were cultivated for 7 days. The sorted CD34 The quantification of the MKs, MK apoptosis, MK polyploidy distribution, and platelet production in the coculture system was performed as previously described.
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| Statistical analysis
The statistical analyses were performed using one-way analysis of variance (ANOVA) among the groups. The subject variables were compared using a v 2 test for categorical variables and a Mann-Whitney U test for continuous variables. Wilcoxon's test for paired data was performed to identify the drug effects. The analyses were performed using GraphPad Prism 6.0 software, and P-values < .05 were considered statistically significant.
| R E SU LTS
3.1 | Decreased percentage and increased levels of ROS and apoptosis in precultured BM EPCs from prolonged isolated thrombocytopenia patients
The baseline percentage of precultivated BM EPCs ( Figure 1A ; 0.04 6 0.01 vs. 0.1 6 0.03, P 5 .03) was significantly lower in the prolonged isolated thrombocytopenia patients than that in the good graft function patients.
Moreover, the intracellular ROS ( Figure 1B; Figure S1 ). Moreover, the spindle-shaped and elongated adherent BM cells were further functionally characterized as EPCs by their DiI-AcLDL uptake and FITC-UEA-1 binding capacities ( Figure 1D ).
| Dysfunction of BM EPCs from prolonged isolated thrombocytopenia patients
To evaluate the BM EPC functions, the double-positive staining with
DiI-AcLDL and FITC-UEA-1, migration, and tube formation of BM EPCs were analyzed on day 7 of cultivation.
A decreased number of double-positive stained cells ( Figure 1D In the precultivated BM EPCs, the flow cytometry data demonstrated remarkably higher levels of phospho-p38 in the BM EPCs from prolonged isolated thrombocytopenia patients than in those from good graft function patients (Supporting Information Figure S2A ; 4664 6 854.2 vs. 2684 6 161.2, P 5 .03). In contrast, the intracellular phosphoAkt (Supporting Information Figure S2B ; 948.5 6 90.1 vs. 1061 6 83.3, P 5 .48), phospho-ERK (Supporting Information Figure S2C ; 4353 6 981.4 vs. 3857 6 415.7, P 5 .74), and phospho-JNK (Supporting Information Figure S2D ; 2239 6 373.5 vs. 2406 6 482.7, P 5 .87) levels
were not significantly different between prolonged isolated thrombocytopenia patients and good graft function patients. In addition, the expression levels of these intracellular proteins detected by flow cytometry were further validated in the 7-day cultivated BM EPCs by western blotting (Supporting Information Figure S2E ). 
| NAC, a p38 inhibitor and atorvastatin reduced the phospho-p38 MAPK activity in BM EPCs from prolonged isolated thrombocytopenia patients
To further explore the reverse effect of the molecular basis of BM EPC dysfunction in prolonged isolated thrombocytopenia patients, we evaluated the phospho-p38 levels in BM EPCs cultivated with different treatments for 7 days. NAC (0.9 6 0.1-fold, P 5 .001), SB203580 (0.9 6 0.1-fold, P < .0001) and atorvastatin (0.8 6 0.1-fold, P < .0001) significantly decreased the phopho-p38 levels analyzed by flow cytometry ( Figure 2F ). The flow cytometry data were further confirmed by the western blotting results ( Figure 2G ). Figure S3A ; 0.4 6 0.2 vs. 0.6 6 0.2, P 5 .13). The apoptosis levels (Supporting Information Figure   S3B ; 15.1 6 2.7 vs. 12.8 6 2.2, P 5 .59) and frequencies of g-H2AX-
positive DNA double-strand breaks (Supporting Information Figure   S3C ; 8668 6 1197 vs. 8916 6 1898, P 5 .65) in the BM CD34 1 cells from prolonged isolated thrombocytopenia patients were similar to those in the cells from good graft function patients. A comet assay was performed to confirm the DNA damage in the BM CD34 1 cells (Supporting Information Figure S3D ). The BM CD34 1 cells from prolonged isolated thrombocytopenia patients had tail lengths (Supporting Information Figure S3E ; 2.3 6 0.9 vs. 2.3 6 0.4, P 5 .70) and comet cell percentages (Supporting Information Figure S3F ; 10.5 6 1.2 vs. 10.1 6 0.7, P 5 .94) that were similar to those in the cells from good graft function patients. However, increased ROS levels (Supporting Information Figure S3G ; 4598 6 467.6 vs. 2850 6 321.8, P 5 .01) were detected in the BM CD34 1 cells from prolonged isolated thrombocytopenia patients compared to those from good graft function patients.
As shown in Supporting Information Figure S3H , the BM CD34 According to our preliminary clinical study, an oral treatment with NAC is a promising therapeutic strategy, leading to a partial recovery of BM EPCs in prolonged isolated thrombocytopenia patients. 6 In addition, ROS augmentation associated with platelet apoptosis has been demonstrated in thrombocytopenia. 43 In the present study, the increased ROS levels in the BM EPCs and CD34 1 cells suggest that ROS may represent a new therapeutic target in prolonged isolated thrombocytopenia patients.
NAC, which is an anti-oxidant, is mainly used as a mucolytic drug and has potential chemo-preventive properties without significant side effects in clinical treatment. 44 NAC played a beneficial role in human engraftment by improving the BM microenvironment in a mouse xenotransplantation study. 22 Consistent with a previous study, 22 we demonstrated that NAC repaired the dysfunctional BM EPCs and further improved megakaryocytopoiesis in prolonged isolated thrombocytopenia patients. Alternatively, atorvastatin has been reported to enhance circulating EPCs in cardiovascular disease 45 and quantitatively and functionally improve BM EPCs in poor graft function patients following allo-HSCT. 26 Although NAC and atorvastatin similarly improved the BM EPCs from prolonged isolated thrombocytopenia patients, NAC demonstrated superior effects on impaired megakaryocytopoiesis compared to atorvastatin. Meanwhile, atorvastatin is associated with HSCT sequelae, such as myopathy and hepatocellular injury. 46 Therefore, NAC, rather than atorvastatin, may represent a promising therapeutic approach for repairing the defective BM EPCs in prolonged isolated thrombocytopenia patients.
However, the pathogenesis of prolonged isolated thrombocytopenia is heterogeneous. Further investigations to determine whether the impaired BM EPCs directly affect megakaryocytopoiesis or act through their immunoregulatory effects in the occurrence of prolonged isolated thrombocytopenia are warranted.
In summary, the reduced and dysfunctional BM EPCs are associated with the occurrence of prolonged isolated thrombocytopenia following allo-HSCT, the impaired BM EPCs can be improved by NAC through a downregulation of the p38 MAPK pathway, and NAC rescued the impaired BM EPCs to support megakaryocytopoiesis.
Although further validation is required, these findings indicate that NAC represents a promising therapeutic approach for repairing the defective BM EPCs in prolonged isolated thrombocytopenia patients.
Therefore, further prospective, multicenter, randomized clinical trials with a large sample size are needed in the future.
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